Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 30% ± 12% | |
peripheral blood | 16 studies | 33% ± 9% | |
brain | 16 studies | 30% ± 18% | |
intestine | 9 studies | 24% ± 11% | |
eye | 9 studies | 29% ± 12% | |
kidney | 6 studies | 26% ± 7% | |
heart | 5 studies | 30% ± 7% | |
lymph node | 5 studies | 29% ± 3% | |
breast | 5 studies | 20% ± 3% | |
liver | 5 studies | 39% ± 17% | |
bone marrow | 4 studies | 27% ± 9% | |
uterus | 4 studies | 33% ± 13% | |
adipose | 4 studies | 41% ± 21% | |
pancreas | 3 studies | 47% ± 8% | |
placenta | 3 studies | 27% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 8580.71 | 459 / 459 | 100% | 152.21 | 1118 / 1118 |
esophagus | 100% | 9085.84 | 1445 / 1445 | 100% | 101.97 | 183 / 183 |
lung | 100% | 8016.42 | 578 / 578 | 100% | 107.53 | 1155 / 1155 |
ovary | 100% | 7985.66 | 180 / 180 | 100% | 99.34 | 430 / 430 |
prostate | 100% | 10446.96 | 245 / 245 | 100% | 168.54 | 502 / 502 |
stomach | 100% | 6584.97 | 359 / 359 | 100% | 91.64 | 286 / 286 |
thymus | 100% | 9487.62 | 653 / 653 | 100% | 138.95 | 604 / 605 |
intestine | 100% | 8417.52 | 966 / 966 | 100% | 93.55 | 526 / 527 |
bladder | 100% | 8541.57 | 21 / 21 | 100% | 97.76 | 503 / 504 |
skin | 100% | 9935.45 | 1809 / 1809 | 100% | 140.53 | 471 / 472 |
uterus | 100% | 8538.05 | 170 / 170 | 100% | 114.87 | 458 / 459 |
brain | 99% | 5078.00 | 2626 / 2642 | 100% | 101.46 | 705 / 705 |
pancreas | 100% | 4233.84 | 327 / 328 | 99% | 90.25 | 177 / 178 |
kidney | 100% | 5349.82 | 89 / 89 | 99% | 82.70 | 892 / 901 |
liver | 100% | 4847.61 | 226 / 226 | 98% | 57.71 | 398 / 406 |
adrenal gland | 100% | 8797.28 | 258 / 258 | 95% | 61.38 | 219 / 230 |
adipose | 100% | 8178.91 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 8636.54 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 125.45 | 29 / 29 |
muscle | 100% | 15015.35 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 8950.09 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 117.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 39.77 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 108.04 | 79 / 80 |
heart | 98% | 5887.64 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 7676.48 | 910 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006397 | Biological process | mRNA processing |
GO_0048255 | Biological process | mRNA stabilization |
GO_0048026 | Biological process | positive regulation of mRNA splicing, via spliceosome |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0007623 | Biological process | circadian rhythm |
GO_0008380 | Biological process | RNA splicing |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0042753 | Biological process | positive regulation of circadian rhythm |
GO_0000956 | Biological process | nuclear-transcribed mRNA catabolic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0016592 | Cellular component | mediator complex |
GO_0016607 | Cellular component | nuclear speck |
GO_0035145 | Cellular component | exon-exon junction complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0046966 | Molecular function | nuclear thyroid hormone receptor binding |
GO_0003677 | Molecular function | DNA binding |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0042809 | Molecular function | nuclear vitamin D receptor binding |
GO_0051219 | Molecular function | phosphoprotein binding |
GO_0030374 | Molecular function | nuclear receptor coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | THRAP3 |
Protein name | Thyroid hormone receptor-associated protein 3 (BCLAF1 and THRAP3 family member 2) (Thyroid hormone receptor-associated protein complex 150 kDa component) (Trap150) THRAP3 protein Thyroid hormone receptor associated protein 3 |
Synonyms | TRAP150 BCLAF2 |
Description | FUNCTION: Involved in pre-mRNA splicing. Remains associated with spliced mRNA after splicing which probably involves interactions with the exon junction complex (EJC). Can trigger mRNA decay which seems to be independent of nonsense-mediated decay involving premature stop codons (PTC) recognition. May be involved in nuclear mRNA decay. Involved in regulation of signal-induced alternative splicing. During splicing of PTPRC/CD45 is proposed to sequester phosphorylated SFPQ from PTPRC/CD45 pre-mRNA in resting T-cells. Involved in cyclin-D1/CCND1 mRNA stability probably by acting as component of the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA. Involved in response to DNA damage. Is excluced from DNA damage sites in a manner that parallels transcription inhibition; the function may involve the SNARP complex. Initially thought to play a role in transcriptional coactivation through its association with the TRAP complex; however, it is not regarded as a stable Mediator complex subunit. Cooperatively with HELZ2, enhances the transcriptional activation mediated by PPARG, maybe through the stabilization of the PPARG binding to DNA in presence of ligand. May play a role in the terminal stage of adipocyte differentiation. Plays a role in the positive regulation of the circadian clock. Acts as a coactivator of the CLOCK-BMAL1 heterodimer and promotes its transcriptional activator activity and binding to circadian target genes . . |
Accessions | Q7Z5U1 A0A3B3ITZ9 Q05D20 Q6PJV4 ENST00000469141.6 Q6P0P7 ENST00000648638.1 Q9Y2W1 ENST00000354618.10 |